145 related articles for article (PubMed ID: 31853972)
1. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer.
Su TH; Tseng TC; Liu CJ; Chou SW; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Kao JH
Int J Cancer; 2020 Aug; 147(3):901-908. PubMed ID: 31853972
[TBL] [Abstract][Full Text] [Related]
2. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
[TBL] [Abstract][Full Text] [Related]
3. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
4. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
Liu TW; Tsai PC; Huang CI; Tsai YS; Wang SC; Ko YM; Lin CC; Chen KY; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
J Formos Med Assoc; 2018 Jan; 117(1):54-62. PubMed ID: 28389143
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
Wu CM; Su FH; Muo CH; Huang JC; Wu MM; Yeh CC
Viruses; 2021 Mar; 13(3):. PubMed ID: 33799370
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
Su TH; Yang HC; Tseng TC; Chou SW; Lin CH; Liu CH; Liu CJ; Chen CL; Kao JH
Mov Disord; 2019 Dec; 34(12):1882-1890. PubMed ID: 31505068
[TBL] [Abstract][Full Text] [Related]
8. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
Chang SC; Hung CT; Li SF; Lee HM; Chung YC; Pai LW; Yang SS
J Formos Med Assoc; 2015 Sep; 114(9):829-34. PubMed ID: 24090634
[TBL] [Abstract][Full Text] [Related]
9. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
Tsai PC; Liu TW; Tsai YS; Ko YM; Chen KY; Lin CC; Huang CI; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
Medicine (Baltimore); 2017 Jun; 96(22):e6984. PubMed ID: 28562549
[TBL] [Abstract][Full Text] [Related]
10. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
[TBL] [Abstract][Full Text] [Related]
11. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
Chen YC; Teng W; Hsieh YC; Chen WT; Jeng WJ; Huang CH; Lin CC; Chen YC; Lin SM; Lin CY; Sheen IS
J Formos Med Assoc; 2019 Aug; 118(8):1239-1246. PubMed ID: 30581103
[TBL] [Abstract][Full Text] [Related]
12. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
[TBL] [Abstract][Full Text] [Related]
13. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
14. [Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].
Li QR; Zhang CJ; Xiong YL; Zhu Y; Tan ZX; Hu YJ; Yuan J; Wang XH
Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):353-6. PubMed ID: 22971280
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
17. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
[TBL] [Abstract][Full Text] [Related]
18. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
Hsu CS; Kao JH; Chao YC; Lin HH; Fan YC; Huang CJ; Tsai PS
Aliment Pharmacol Ther; 2013 Aug; 38(4):415-23. PubMed ID: 23802888
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
